Germany-based biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases
Kupando has raised €23M across 2 funding rounds from 7 investors, most recently a Series A round in Mar 2026. Based in Berlin, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
